Motixafortide
Motixafortide is a CXCR4 receptor antagonist used to mobilize hematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous transplantation in patients with multiple myeloma or lymphoma. By blocking the CXCR4-SDF-1α/CXCL12 axis, it disrupts stem cell retention in the bone marrow niche, allowing these cells to circulate for harvesting. This medication is administered as a subcutaneous injection typically given prior to stem cell collection procedures.
Motixafortide is a CXCR4 inhibitor used to mobilize stem cells for collection before autologous transplantation in blood cancer patients.
Key facts at a glance
- ATC
- L03AX23
- RxNorm
- 2664896
- Generic
- Motixafortide
- Class
- atc-l03
- Brands
- Aphexda
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Motixafortide is indicated for mobilizing hematopoietic stem cells from bone marrow to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma and lymphoma.
Motixafortide is a selective CXCR4 receptor antagonist that blocks the binding of stromal-derived factor-1α (SDF-1α/CXCL12), the cognate ligand for CXCR4. This disruption of the CXCR4-SDF-1α interaction releases hematopoietic stem and progenitor cells from their bone marrow niche into the peripheral circulation.
Motixafortide is administered as a subcutaneous injection, typically 0.24 mg/kg once daily. Common adverse effects include injection site reactions, transient leukocytosis, and musculoskeletal pain. It should be used with granulocyte colony-stimulating factor (G-CSF) for optimal stem cell mobilization. Patients should be monitored for potential effects on cardiac conduction and hypersensitivity reactions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy